Boundless Bio, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BOLD research report →
Companyboundlessbio.com
Boundless Bio, Inc. , a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers.
- CEO
- Zachary Hornby
- IPO
- 2016
- Employees
- 64
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $31.90M
- P/E
- -0.57
- P/S
- 0.00
- P/B
- 0.37
- EV/EBITDA
- -1.10
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -53.60%
- ROIC
- -45.06%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-58,197,000 · 10.96%
- EPS
- $-2.60 · 32.47%
- Op Income
- $-63,552,000
- FCF YoY
- 25.51%
Performance & Tape
- 52W High
- $1.68
- 52W Low
- $0.96
- 50D MA
- $1.34
- 200D MA
- $1.23
- Beta
- 0.95
- Avg Volume
- 219.56K
Get TickerSpark's AI analysis on BOLD
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 23, 26 | Oien Jessica | other | 220,000 |
| Jan 23, 26 | Hassig Christian | other | 230,000 |
| Jan 23, 26 | Doebele Robert | other | 230,000 |
| Jan 23, 26 | Hornby Zachary | other | 600,000 |
| Jan 23, 26 | HINKLE DAVID A | other | 140,000 |
| Jun 23, 25 | Brennan Christine | other | 16,000 |
| Jun 23, 25 | Christensen James | other | 16,000 |
| Jun 23, 25 | Lew Jennifer | other | 16,000 |
| Jun 23, 25 | Lim Jonathan E | other | 24,000 |
| Jun 23, 25 | Burow Kristina | other | 16,000 |
Our BOLD Coverage
We haven't published any research on BOLD yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BOLD Report →